STT3A Antibody

What is STT3A Antibody?

STT3A antibodies target the catalytic subunit of the oligosaccharyltransferase (OST) complex, which facilitates the transfer of glycan molecules to asparagine residues in nascent proteins during N-glycosylation . STT3A is a 705-amino-acid protein (81 kDa) localized in the endoplasmic reticulum (ER) and is highly expressed in the placenta, liver, muscle, and pancreas .

Key Features of STT3A Antibodies

Role in Cancer Biology

STT3A antibodies have been instrumental in uncovering the protein’s involvement in tumor progression:

Genetic Disorders

• Congenital Disorders of Glycosylation (CDG):

  • Heterozygous STT3A mutations cause autosomal-dominant CDG type I, characterized by skeletal anomalies, intellectual disability, and neuromusculoskeletal symptoms .

  • Antibody-based studies confirm abnormal glycosylation profiles in patient-derived fibroblasts .

Technical Validation and Best Practices

• Specificity: Antibodies like ab320831 show no cross-reactivity with STT3B in dot blot assays .

• Knockout Validation: STT3A knockout cell lines (e.g., HEK-293T) confirm antibody specificity .

• Buffer Compatibility: Most antibodies are stable in PBS with 0.02% sodium azide and 50% glycerol, stored at -20°C .

Future Directions

STT3A antibodies are pivotal for advancing therapeutic strategies. For example, small-molecule inhibitors like NGI-1, which block STT3A activity, are under investigation for LUAD treatment . Additionally, targeting STT3A-mediated PD-L1 glycosylation could enhance immunotherapy efficacy .